The Variant on the Move
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
Your Edge In Biotech.
Frontpoints Latest Articles
Califf Gets FDA Nod, Novo Acquires Dicerna, & a Shrewd Investment in Pittsburgh
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
Pfizer’s Game-Changer, Moderna-NIH Feud Goes Public, & Genomics England Ends Dx Odysseys
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
The Vaccine Pile-Up, Regeneron Crushes It, CF Foundation Bets on Flagship Combos
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
Pfizer Vaccine OK’d for Kids, Merck Ensures Global Access, and Maraganore Passes Torch
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
Biogen’s Face-plant, an Interchangeable Humira, & Boosters OK’d
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
Collins Exits NIH; WHO Backs GSK Malaria Vaccine; RA, MPM, Atlas Reload
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
Merck Buys Acceleron, Regeneron Antibody Saves Lives, & Moderna Invests in Cambridge
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More